Catalyst overview
Research summary
This catalyst tracks a Phase 2 update for Sonelokimab in Axial spondyloarthritis . The expected timing is based on the latest available company guidance and may change.
S-OLARIS. 1/8/25- Ph2 initiated in axSpa. 5/12/25- Trial ongoing. 8/5/25- Topline data in Q1 2026. 11/05/25:- Q1 2026 primary endpoint readout for Phase 2 S-OLARIS axial spondyloarthritis trial reiterated. 02/02/26:- S-OLARIS Phase 2 axSpA primary endpoint readout scheduled for February 2026 and to be presented at Investor Day. 02/22/26:- S-OLARIS Phase 2 axSpA topline data reported; 81% ASAS40 at week 12; detailed data presentation February 23, 2026. 05/10/26:- S-OLARIS described as ongoing Phase 2 axial spondyloarthritis trial; no new data or timelines disclosed. 08/10/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.